Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 243452
Licensed Product(s) shall mean any Compound ISS or any pharmaceutical product containing one or more Compound ISS as an active ingredient, alone or in combination with other active ingredients (including ISS) or inactive ingredients, for administration in accordance with the Forms of Administration. For the avoidance of doubt, Licensed Products may include (a) ISS together with Compound ISS and (b) any pharmaceutical product containing one or more ISS together with Compound ISS, but shall not include (x) ISS in the absence of Compound ISS or (y) any pharmaceutical product containing one or more ISS in the absence of Compound ISS.
Compound ISS shall mean any ISS which is (a) covalently bound or otherwise chemically conjugated with the Antigen and/or (b) mixed or otherwise combined with the Antigen. For the avoidance of doubt, this specifically includes instances where the Antigen is both chemically conjugated with the ISS and also mixed or otherwise combined with the ISS. Notwithstanding the foregoing, in the case of prophylaxis of HBV, Compound ISS does not include instances where the Antigen is mixed or otherwise combined., but not covalently bound or otherwise chemically conjugated., with the ISS.
HBV shall mean hepatitis B virus.
ISS shall mean any immunostimulatory oligonucleotide (without limitation as to structure or length) containing a nucleic acid sequence which can activate or stimulate an immune response alone or in combination with other immune responses in vitro or in vivo and wherein the nucleosides in the nucleic acid sequence can be naturally occurring or not naturally occurring and such nucleosides can be connected through any form of naturally occurring or not naturally occurring linkage.
IPSCIO Record ID: 212650
â€œLicensed Productâ€ shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.
Patents Claiming Priority to Patent Application Serial No. 08/276,358
IPSCIO Record ID: 372620
Licensor grants an exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the Territory other than the United States, for any and all uses in the Territory in the Field.
Licensor grants a non-exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the United States, for any and all uses in the Territory in the Field.
For the Non-Exclusive License Grant, in the event that the making, having made, use, offer for sale, sale or import by Licensee, or its Related Parties, of Licensed Vaccine or Products would infringe during the term of this Agreement a claim of issued letters patent which Licensor owns and which patents are not covered by the grant, Licensor grants, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under such issued letters patent for Licensee and its Related Parties to develop, make, have made, use, sell, offer for sale or import Licensed Vaccines and Products in the Territory.
If Licensee desires to use any trademark identified by Licensor as of the Effective Date for use for the Licensed Vaccine and/or Product in the Territory, it will include without limitation the trademark Heplisavâ„¢.
Hepatitis B Surface Antigen shall mean an immunogenically effective Hepatitis B Surface Antigen protein that is produced by recombinant DNA technology.
x-ISS shall mean the adjuvant, an immunostimulatory sequence (ISS) composed of the 22mer phosphorothioate oligonucleotide sequence 5 TGA CTG TGA ACG TIC GAG ATG A3.
Patents and know-how include
ISSs, Compositions and Methods of Use;
DNA Molecules Coding for FMDH Control Regions; and,
Immunostimulatory Nucleic Acid Molecules.
The trademark is Heplisavâ„¢.
Heplisav-B is a vaccine used in adults 18 and over to prevent hepatitis B, a viral infection of the liver.
IPSCIO Record ID: 203335
Licensee accepts a worldwide non-exclusive license to make and have made, to use and have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold Oligonucleotides solely for any and all preclinical and research purposes, the additional products.
Licensor grants an exclusive, worldwide license, with the right to sublicense, to all improvements conceived or made during such term by Licensor employees or consultants or any other third party working for, on behalf of or under the supervision of, Licensor, and any patent rights claiming such improvements including any continuations, divisionals, reexaminations, reissues or extensions of any such patent rights, and any and all foreign patents and patent applications corresponding thereto, to the extent they relate to animal and/or veterinary applications and uses for Oligonucleotides.
Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.
IPSCIO Record ID: 249711
Licensor grants to the United Kingdom Licensee and to any affiliates the following licenses, with the right to grant sublicenses, under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field all Products and/or Combinations, subject to the following
– For Prophylactic Immunization within the Field, Licensor grants a Co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
â€¢ HPV ANTIGENS
â€¢ HBV ANTIGENS
â€¢ INFLUENZA ANTIGENS
â€¢ Chlamydia ANTIGENS
â€¢ Mycobacterium ANTIGENS
â€¢ RSV ANTIGENS
â€¢ Malaria ANTIGENS
– For Prophylactic Immunization within the Field, Licensor grants a non-exclusive license for the following Licensed Antigens and no other Antigens
â€¢ HIV ANTIGENS
– For Therapeutic immunization within the Field Licensor grants a co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
â€¢ HPV ANTIGENS
â€¢ HBV ANTIGENS
â€¢ Chlamydia ANTIGENS
â€¢ Mycobacterium ANTIGENS
The patents relate to the use of Nucleic Acid.
Specific Field shall mean the use of Adjuvant as part of or in conjunction with a DNA Vaccine or other than in combination with a Licensed Antigen.
IPSCIO Record ID: 204355
In the original restated license, Licensor grants a world-wide exclusive license under Licensed Patents and Licensed Know-How, to make, use, offer to sell, sell and import Licensed Products in the Exclusive Licensed Field.
The licensed know-how includes chemical structures, manufacturing methods and Algorithms, object code, source code and any other embodiments of methods or processes useful for predicting the melting temperature of MGB Oligonucleotides, whether patented, copyrighted, or not.
IPSCIO Record ID: 203459
This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.
The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.
The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.
The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.
The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.